Q-omics provides the consensus-scored PRKG1 profile across patient tissues and cancer cell-line models. PRKG1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PRKG1 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, PRKG1 protein abundance shows 33,100 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, THCA, and LSCC as cancer lineages where PRKG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKG1 survival associations across molecular data types. PRKG1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKG1 RNA expression–survival associations across cancer types. High PRKG1 expression shows unfavorable associations in BLCA, STAD and UVM, but favorable associations in KIRC, ACC and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PRKG1 RNA expression.
This table summarizes PRKG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRKG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKG1 shows lower tumor expression in THCA, BLCA, LUSC, LUAD, KIRP and UCEC. The THCA box plot shows higher PRKG1 RNA expression in normal versus tumor tissue (log2 FC = −2.354, t-test p < 0.001).
This table shows molecular features associated with PRKG1 in patient tissues and cancer cell lines. In patient samples, PRKG1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
